Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Yescarta (axicabtagene ciloleucel)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cabaret Biotech, Fosun Kite, Gilead, National Cancer Institute

Drug class:

CD19-targeted CAR-T immunotherapy

Related drugs:

‹

murine autologous anti-CD19 CART cells (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

lisocabtagene maraleucel (19)

tisagenlecleucel-T (15)

brexucabtagene autoleucel (4)

relmacabtagene autoleucel (2)

CAR-T19/CAR-T22 immunotherapy (1)

JNJ-90014496 (1)

ATHENA CAR-T (0)

Anti-CD19 CAR-T (0)

Anti-CD19-CAR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

Autologous CAR-T cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR19T2 T cells (0)

CAR20.19.22 T (0)

CARCIK-CD19 (0)

CART-138/BCMA/19/more (0)

CD19 CAR T cells (0)

CD19 UCART cells (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19 specific CAR T cell therapy (0)

CD19 targeted CAR-T (0)

CD19-7×19 CAR-T (0)

CD19-CAR-DNT (0)

CD19-CAR-T2 cells (0)

CD19-CAR.CD45RA- negative T-cells (0)

CD19-CAR_Lenti T cells (0)

CD19-CD22 CAR-T (0)

CD19-CD34 CAR transduced T cells (0)

CD19-CD34t metabolically programmed CAR transduced T-cells (0)

CD19-PD1-CART cell (0)

CD19-targeted CAR-T cells (0)

CD19/BAFF-R dual CAR T (0)

CD19/BCMA targeted CAR T-cells (0)

CD19/CD20 CAR T-cells (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19CAR/virus specific T cell therapy (0)

CD19x22 CAR T (0)

CD20-CD19 cCAR T cells (0)

CD22/CD19 CAR T (0)

CLBR001/SWI019 (0)

CMV/CD19 bi-Specific CAR T (0)

CTA30X UCAR-T (0)

DDCAR-CD19 T-cells (0)

EGFRt/19-28z/4-1BBL CAR T cells (0)

IM19 CAR-T cells (0)

MB-CAR-T19-22 (0)

MB-CART 19.1 (0)

MM-specific universal CAR T (0)

P-CD19CD20-ALLO1 (0)

RPM CD19-mbIL15-CAR-T cells (0)

SCRI-CAR19v1 (0)

SCRI-CAR19x22v2 (0)

SCRI-huCAR19v1 (0)

SCRI-huCAR19v2 (0)

SNUH-CD19-CAR-T (0)

STK-009/SYNCAR-001 (0)

Senl_H19x22P (0)

UCD19 CAR T Cells (0)

XYF19 CAR-T cells (0)

alloCART-19 cell therapy (0)

anti-CD19 CAR T-cells (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T therapy (0)

anti-CD19 DASH CAR-T (0)

anti-CD19-CAR (0)

anti-CD19-CAR γδT (0)

anti-CD19/CD22 CAR-T cells (0)

autologous 3rd generation CD19-targeting CAR T cell therapy (0)

autologous TriCAR T (0)

human derived (0)

huCART19-IL18 (0)

human anti CD19 CAR-T cells (0)

humanized CD19 CAR-T cell therapy (0)

humanized CD19 CAR-T cells (0)

iC9-CAR19 cells (0)

multi-CAR-T cell therapy (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

murine CD19 CAR-T cell therapy (0)

murine autologous anti-CD19 CART cells (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

›

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Lymphoma	No biomarker	Lymphoma	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1	axicabtagene ciloleucel Resistant: A1 - Approval axicabtagene ciloleucel Resistant : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	axicabtagene ciloleucel Sensitive: A2 - Guideline axicabtagene ciloleucel Sensitive : A2	axicabtagene ciloleucel Sensitive: A2 - Guideline axicabtagene ciloleucel Sensitive : A2
MYC positive + BCL2 positive	Diffuse Large B Cell Lymphoma	MYC positive + BCL2 positive	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
PAX5 mutation	Diffuse Large B Cell Lymphoma	PAX5 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
IRF8 mutation	Diffuse Large B Cell Lymphoma	IRF8 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
CD19 mutation	Diffuse Large B Cell Lymphoma	CD19 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
CD58 mutation	Diffuse Large B Cell Lymphoma	CD58 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
LDH elevation	Lymphoma	LDH elevation	Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
IL6 elevation	Diffuse Large B Cell Lymphoma	IL6 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
CXCL8 elevation	Diffuse Large B Cell Lymphoma	CXCL8 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
CCL4 elevation	Diffuse Large B Cell Lymphoma	CCL4 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
IL27 elevation	Diffuse Large B Cell Lymphoma	IL27 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3